Mark Lebwohl1, Stephen Tyring2, Michael Bukhalo3, Javier Alonso-Llamazares4, Martin Olesen5, David Lowson5, Paul Yamauchi6. 1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; 2. Department of Dermatology, University of Texas, Houston, Texas; 3. Altman Dermatology Associates, Arlington Heigrits, Illinois; 4. Department of Dermatology, VA Medical Center, Miami, Florida; 5. LEO Pharma A/S, Ballerup, Denmark; 6. Dermatology Institute and Skin Care Center, Santa Monica, California.
Abstract
OBJECTIVE: To evaluate the efficacy of fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD). DESIGN: Patients were randomized (100:101:101) to receive Cal/BD foam, Cal foam, or BD foam once daily for four weeks. SETTING:Twenty-eight United States centers. PARTICIPANTS: 302 patients (≥18 years) with Psoriasis vulgaris (plaque Psoriasis; ≥mild disease severity by physicians global assessment). MEASUREMENTS: Treatment success of the body ("clear"/"almost clear" from baseline moderate/severe disease; "clear" from baseline mild disease). Involved scalp treatment success was an additional endpoint. RESULTS: Most patients (76%) had moderate Psoriasis of the body (66% for scalp). At Week 4, 45 percent of Cal/BD foam patients achieved treatment success, significantly more than Cal foam (14.9%; OR 4.34 [95%CI 2.16,8.72] P<0.001) or BD foam (30.7%; 1.81 [1.00,3.26] P=0.047). Fifty-three percent of Cal/BD foam patients achieved treatment success of the scalp, significantly greater than Cal foam (35.6%; 1.91 [1.09,3.35] P=0.021), but not BD foam (47.5%; 1.24 [0.71,2.16] P=0.45). Mean modified Psoriasis area and severity index (population baseline 7.6) improved in all groups, with statistically significant differences in Week 4 Cal/BD foam score (2.37) versus Cal foam (4.39; mean difference -2.03 [-2.63][-1.43] P<0.001) and BD foam (3.37; -1.19 [-1.80][-0.59] P<0.001). Four (Cal/BD), 10 (Cal), and 8 (BD) adverse drug reactions were reported. CONCLUSION: Cal/BD foam was significantly more effective than Cal foam and BD foam in providing treatment success at Week 4 and effective on involved scalp. TRIAL REGISTRATION: NCT01536938.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of fixed combination aerosol foamcalcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD). DESIGN:Patients were randomized (100:101:101) to receive Cal/BD foam, Cal foam, or BD foam once daily for four weeks. SETTING: Twenty-eight United States centers. PARTICIPANTS: 302 patients (≥18 years) with Psoriasis vulgaris (plaque Psoriasis; ≥mild disease severity by physicians global assessment). MEASUREMENTS: Treatment success of the body ("clear"/"almost clear" from baseline moderate/severe disease; "clear" from baseline mild disease). Involved scalp treatment success was an additional endpoint. RESULTS: Most patients (76%) had moderate Psoriasis of the body (66% for scalp). At Week 4, 45 percent of Cal/BD foampatients achieved treatment success, significantly more than Cal foam (14.9%; OR 4.34 [95%CI 2.16,8.72] P<0.001) or BD foam (30.7%; 1.81 [1.00,3.26] P=0.047). Fifty-three percent of Cal/BD foampatients achieved treatment success of the scalp, significantly greater than Cal foam (35.6%; 1.91 [1.09,3.35] P=0.021), but not BD foam (47.5%; 1.24 [0.71,2.16] P=0.45). Mean modified Psoriasis area and severity index (population baseline 7.6) improved in all groups, with statistically significant differences in Week 4 Cal/BD foam score (2.37) versus Cal foam (4.39; mean difference -2.03 [-2.63][-1.43] P<0.001) and BD foam (3.37; -1.19 [-1.80][-0.59] P<0.001). Four (Cal/BD), 10 (Cal), and 8 (BD) adverse drug reactions were reported. CONCLUSION: Cal/BD foam was significantly more effective than Cal foam and BD foam in providing treatment success at Week 4 and effective on involved scalp. TRIAL REGISTRATION: NCT01536938.
Authors: G Girolomoni; G A Vena; F Ayala; S P Cannavò; O De Pità; S Chimenti; A Peserico Journal: G Ital Dermatol Venereol Date: 2012-12 Impact factor: 2.011
Authors: Joana Ribeiro Costa de Faria; Aline Rezende Aarão; Luiz Miguel Zabaleta Jimenez; Oscar Hernández Silva; João Carlos Regazzi Avelleira Journal: An Bras Dermatol Date: 2010 Sep-Oct Impact factor: 1.896
Authors: S J M de Brouwer; H van Middendorp; C Stormink; F W Kraaimaat; F C G J Sweep; E M G J de Jong; J Schalkwijk; A Eijsbouts; A R T Donders; P C M van de Kerkhof; P L C M van Riel; A W M Evers Journal: Br J Dermatol Date: 2014-04 Impact factor: 9.302
Authors: U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar Journal: Arch Dermatol Res Date: 2010-09-21 Impact factor: 3.017
Authors: John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel Journal: J Dermatolog Treat Date: 2015-10-07 Impact factor: 3.359
Authors: Siegfried Segaert; Neil H Shear; Andrea Chiricozzi; Diamant Thaçi; Jose-Manuel Carrascosa; Helen Young; Vincent Descamps Journal: Dermatol Ther (Heidelb) Date: 2017-08-07
Authors: C Paul; L Stein Gold; F Cambazard; R E Kalb; D Lowson; B Bang; C E M Griffiths Journal: J Eur Acad Dermatol Venereol Date: 2016-08-17 Impact factor: 6.166